Ken Griffin’s Aimmune Therapeutics AIMT Stock Holding History

Ken Griffin’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-16,600	Closed	-$572K	–	11889
2020 Q3	$572K	Sell	16,600 -32,000	-66%	-$682K	﹤0.01%	7058
2020 Q2	$812K	Sell	48,600 -55,300	-53%	-$939K	﹤0.01%	6215
2020 Q1	$1.5M	Sell	103,900 -33,800	-25%	-$864K	﹤0.01%	4622
2019 Q4	$4.61M	Sell	137,700 -33,000	-19%	-$923K	﹤0.01%	3178
2019 Q3	$3.57M	Buy	170,700 +92,600	+119%	+$1.89M	﹤0.01%	3580
2019 Q2	$1.63M	Buy	78,100 +39,400	+102%	+$811K	﹤0.01%	4875
2019 Q1	$865K	Sell	38,700 -8,900	-19%	-$210K	﹤0.01%	5848
2018 Q4	$1.14M	Buy	47,600 +35,800	+303%	+$926K	﹤0.01%	5114
2018 Q3	$322K	Sell	11,800 -12,000	-50%	-$339K	﹤0.01%	7450
2018 Q2	$640K	Buy	+23,800	New	+$728K	﹤0.01%	5977

Ken Griffin's AIMT Position: Q4 2020 in Review

Ken Griffin sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 75,551 shares — an estimated $2.6M sold.

Ken Griffin first reported a position in AIMT in Q2 2016 and held it in 17 quarters. The position peaked at $13.9M in Q3 2017. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

Ken Griffin reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
Ken Griffin sold 75,551 Aimmune Therapeutics shares in Q4 2020, an estimated $2.6M.
Ken Griffin first reported a position in Aimmune Therapeutics in Q2 2016 and held it in 17 quarters.
Ken Griffin's Aimmune Therapeutics position peaked at $13.9M in Q3 2017.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Citadel Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.